The purpose of this study is to determine whether survival can be prolonged in patients with castration-resistant prostate cancer who receive dasatinib in addition to docetaxel and prednisone.

Eligibility Criteria

Patients may be eligible to participate in this clinical trial if they meet the following criteria:

• Histologically diagnosed prostate cancer
• Evidence of metastatic disease
• Evidence of progression, by rising PSA, nodal/visceral disease, bone scan, or local recurrence
• Serum testosterone ≤ 50 ng/dL
• Must be able to take oral medications
• Performance status zero, one, or two

Exclusion Criteria

Patients who meet the following criteria are not eligible to participate in the clinical trial:

• Symptomatic brain or leptomeningeal metastases
• Clinically significant cardiovascular disease
• Pleural or pericardial effusion
• Currently active second malignancy
• Uncontrolled intercurrent illness
• Prior cytotoxic chemotherapy, with the exception of estramustine

Compensation

Participants will receive no payment for participation, ideas, or products that may result from this study.

For more information, contact Karla Morris at 919-668-8375.